337 related articles for article (PubMed ID: 27625747)
1. Treatment of diabetic retinopathy: Recent advances and unresolved challenges.
Stewart MW
World J Diabetes; 2016 Aug; 7(16):333-41. PubMed ID: 27625747
[TBL] [Abstract][Full Text] [Related]
2. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.
Krick TW; Bressler NM
Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor inhibition and proliferative diabetic retinopathy, a changing treatment paradigm?
Wu L; Acón D; Wu A; Wu M
Taiwan J Ophthalmol; 2019; 9(4):216-223. PubMed ID: 31942426
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature.
Chatziralli I; Loewenstein A
Pharmaceutics; 2021 Jul; 13(8):. PubMed ID: 34452097
[No Abstract] [Full Text] [Related]
5. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
[TBL] [Abstract][Full Text] [Related]
6. Current and Future Pharmacologic Therapies for Diabetic Retinopathy.
Villegas VM; Schwartz SG
Curr Pharm Des; 2018; 24(41):4903-4910. PubMed ID: 30706803
[TBL] [Abstract][Full Text] [Related]
7. The Evolving Treatment of Diabetic Retinopathy.
Mansour SE; Browning DJ; Wong K; Flynn HW; Bhavsar AR
Clin Ophthalmol; 2020; 14():653-678. PubMed ID: 32184554
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor and diabetic macular edema.
Lally DR; Shah CP; Heier JS
Surv Ophthalmol; 2016; 61(6):759-768. PubMed ID: 27045225
[TBL] [Abstract][Full Text] [Related]
9. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
[TBL] [Abstract][Full Text] [Related]
10. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW;
JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039
[TBL] [Abstract][Full Text] [Related]
11. Current trends in the pharmacotherapy of diabetic retinopathy.
Kumar B; Gupta SK; Saxena R; Srivastava S
J Postgrad Med; 2012; 58(2):132-9. PubMed ID: 22718058
[TBL] [Abstract][Full Text] [Related]
12. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
Hussain RM; Ciulla TA
Expert Opin Biol Ther; 2016; 16(3):365-74. PubMed ID: 26674182
[TBL] [Abstract][Full Text] [Related]
13. The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy.
Zhao Y; Singh RP
Drugs Context; 2018; 7():212532. PubMed ID: 30181760
[TBL] [Abstract][Full Text] [Related]
14. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
; Gross JG; Glassman AR; Jampol LM; Inusah S; Aiello LP; Antoszyk AN; Baker CW; Berger BB; Bressler NM; Browning D; Elman MJ; Ferris FL; Friedman SM; Marcus DM; Melia M; Stockdale CR; Sun JK; Beck RW
JAMA; 2015 Nov; 314(20):2137-2146. PubMed ID: 26565927
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab for the management of diabetic macular edema.
Stefanini FR; Arevalo JF; Maia M
World J Diabetes; 2013 Apr; 4(2):19-26. PubMed ID: 23593532
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
17. Current intravitreal pharmacologic therapies for diabetic macular edema.
Colucciello M
Postgrad Med; 2015 Aug; 127(6):640-53. PubMed ID: 26036708
[TBL] [Abstract][Full Text] [Related]
18. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
Emerson MV; Lauer AK
BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122
[TBL] [Abstract][Full Text] [Related]
19. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.
Hutton DW; Stein JD; Bressler NM; Jampol LM; Browning D; Glassman AR;
JAMA Ophthalmol; 2017 Jun; 135(6):576-584. PubMed ID: 28492920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
